Moderna or Pfizer Booster Works Better For People Vaccinated With J&J: Study
People who received Johnson & Johnson's Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published Wednesday showed.
Photo: TYT
Washington (AFP): People who received Johnson & Johnson's Covid-19 vaccine may benefit from a booster dose of Pfizer or Moderna, preliminary results of a US study published Wednesday showed.
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States because it looked at the possibility of "mixing" vaccines -- using a different vaccine than the initial doses for the booster shot -- which is not currently allowed in the country.
The study was conducted on 458 adults who had been vaccinated with one of three US-approved brands (Pfizer, Moderna or J&J) for at least 12 weeks.
These three groups were each divided into three new groups to receive one of the available vaccines as a booster. The nine groups consisted of about 50 people each.
Researchers then analyzed antibody levels 15 days after the booster shot.
For people originally inoculated with J&J, antibody levels were four times higher after a J&J booster, 35 times higher after a Pfizer booster and 76 times higher after a Moderna booster.
And antibody levels for those who had originally received Moderna shots were higher "irrespective of the booster vaccine administered," when compared with those who had initially received Pfizer or J&J, the study said.
Additionally, "no safety concerns were identified" after booster doses were administered, it found.
The study, which has not yet been peer-reviewed, has several limitations, however.
The number of participants was small, and the immune response could evolve over time, beyond the 15 days observed during the study.
"Important not to get too carried away with the findings," tweeted Peter Hotez, a professor at Baylor College of Medicine.
Results from trials on a second J&J booster shot conducted by the company itself were "impressive," he said.
The NIH study should fuel discussions by a US Food and Drug Administration (FDA) expert committee, which is scheduled to consider applications for a booster dose from Moderna and J&J on Thursday and Friday, respectively.
A booster from Pfizer has already been approved in the United States for certain populations, such as people aged 65 or older, adults with high-risk medical conditions and those in jobs where they are frequently exposed to the coronavirus.
-
Indigenous people march in Brazil to demand land demarcation
2024-04-24 -
Talks on global plastic treaty begin in Canada
2024-04-24 -
Colombian court recognizes environmental refugees
2024-04-24 -
Asia hit hardest by climate and weather disasters last year, says UN
2024-04-23 -
Denmark launches its biggest offshore wind farm tender
2024-04-22 -
Nobel laureate urges Iranians to protest 'war against women'
2024-04-22 -
'Human-induced' climate change behind deadly Sahel heatwave: study
2024-04-21 -
Moldovan youth is more than ready to join the EU
2024-04-18 -
UN says solutions exist to rapidly ease debt burden of poor nations
2024-04-18 -
Climate impacts set to cut 2050 global GDP by nearly a fifth
2024-04-18